Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401

NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has...
March 19, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
March 16, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results

NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced...
March 08, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
January 26, 2018 10:21 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing...
January 24, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
January 22, 2018 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
January 04, 2018 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers...
December 13, 2017 08:36 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
December 08, 2017 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting

NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right